Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(6):747–756. doi: 10.1038/bjc.1997.456

Reduced expression of neurofibromin in human meningiomas.

V Sundaram 1, J H Lee 1, J A Harwalkar 1, D J Stein 1, M Roudebush 1, D W Stacey 1, M Golubic 1
PMCID: PMC2228040  PMID: 9310240

Abstract

Meningiomas are common, mostly benign, tumours arising from leptomeningeal cells of the meninges, which frequently contain mutations in the neurofibromatosis type 2 (NF2) gene. In this study, we analysed a protein product of the neurofibromatosis type 1 (NF1) gene, neurofibromin, in human established leptomeningeal cells LTAg2B, in 17 sporadic meningiomas and in a meningioma from a patient affected by NF2. The expression level of neurofibromin was determined by immunoblotting and immunoprecipitation with anti-neurofibromin antibodies. The functional status of neurofibromin was analysed through its ability to stimulate the intrinsic GTPase activity of p21 ras. In the cytosolic extracts of four sporadic meningiomas and in the NF2-related meningioma, the expression level and the GTPase stimulatory activity of neurofibromin were drastically reduced compared with the level present in the human brain, human established leptomeningeal cells LTAg2B and the remaining 13 meningiomas. Our results suggest that neurofibromin is expressed in leptomeningeal cells LTAg2B and in most meningiomas, i.e. tumours derived from these cells. The reduced expression and GTPase stimulatory activity of neurofibromin was found in about 23% of meningiomas and in the single NF2-related meningioma analysed. These results suggest that decreased levels of neurofibromin in these tumours may contribute to their tumorigenesis.

Full text

PDF
747

Images in this article

749Figure 1
on p.749
749Figure 2
on p.749
750Figure 3
on p.750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvanitis D., Malliri A., Antoniou D., Linardopoulos S., Field J. K., Spandidos D. A. Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. In Vivo. 1991 Jul-Aug;5(4):317–321. [PubMed] [Google Scholar]
  2. Baba H., Fuss B., Urano J., Poullet P., Watson J. B., Tamanoi F., Macklin W. B. GapIII, a new brain-enriched member of the GTPase-activating protein family. J Neurosci Res. 1995 Aug 15;41(6):846–858. doi: 10.1002/jnr.490410615. [DOI] [PubMed] [Google Scholar]
  3. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990 Nov 16;63(4):851–859. doi: 10.1016/0092-8674(90)90151-4. [DOI] [PubMed] [Google Scholar]
  4. Basu T. N., Gutmann D. H., Fletcher J. A., Glover T. W., Collins F. S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992 Apr 23;356(6371):713–715. doi: 10.1038/356713a0. [DOI] [PubMed] [Google Scholar]
  5. Bernards A., Haase V. H., Murthy A. E., Menon A., Hannigan G. E., Gusella J. F. Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and absence of expression in a neuroblastoma line. DNA Cell Biol. 1992 Dec;11(10):727–734. doi: 10.1089/dna.1992.11.727. [DOI] [PubMed] [Google Scholar]
  6. Bollag G., McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 1991 Jun 13;351(6327):576–579. doi: 10.1038/351576a0. [DOI] [PubMed] [Google Scholar]
  7. Bos J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed] [Google Scholar]
  8. Collins V. P., Nordenskjöld M., Dumanski J. P. The molecular genetics of meningiomas. Brain Pathol. 1990 Sep;1(1):19–24. doi: 10.1111/j.1750-3639.1990.tb00634.x. [DOI] [PubMed] [Google Scholar]
  9. Daston M. M., Scrable H., Nordlund M., Sturbaum A. K., Nissen L. M., Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron. 1992 Mar;8(3):415–428. doi: 10.1016/0896-6273(92)90270-n. [DOI] [PubMed] [Google Scholar]
  10. DeClue J. E., Papageorge A. G., Fletcher J. A., Diehl S. R., Ratner N., Vass W. C., Lowy D. R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992 Apr 17;69(2):265–273. doi: 10.1016/0092-8674(92)90407-4. [DOI] [PubMed] [Google Scholar]
  11. Estes M. L., Ransohoff R. M., McMahon J. T., Jacobs B. S., Barna B. P. Characterization of adult human astrocytes derived from explant culture. J Neurosci Res. 1990 Dec;27(4):697–705. doi: 10.1002/jnr.490270430. [DOI] [PubMed] [Google Scholar]
  12. Golubić M., Roudebush M., Dobrowolski S., Wolfman A., Stacey D. W. Catalytic properties, tissue and intracellular distribution of neurofibromin. Oncogene. 1992 Nov;7(11):2151–2159. [PubMed] [Google Scholar]
  13. Heim R. A., Silverman L. M., Farber R. A., Kam-Morgan L. N., Luce M. C. Screening for truncated NF1 proteins. Nat Genet. 1994 Nov;8(3):218–219. doi: 10.1038/ng1194-218. [DOI] [PubMed] [Google Scholar]
  14. Kujas M. Meningioma. Curr Opin Neurol. 1993 Dec;6(6):882–887. doi: 10.1097/00019052-199312000-00009. [DOI] [PubMed] [Google Scholar]
  15. Lee J. H., Sundaram V., Stein D. J., Kinney S. E., Stacey D. W., Golubić M. Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery. 1997 Mar;40(3):578–587. doi: 10.1097/00006123-199703000-00031. [DOI] [PubMed] [Google Scholar]
  16. Lekanne Deprez R. H., Riegman P. H., Groen N. A., Warringa U. L., van Biezen N. A., Molijn A. C., Bootsma D., de Jong P. J., Menon A. G., Kley N. A. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene. 1995 Apr 20;10(8):1521–1528. [PubMed] [Google Scholar]
  17. Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K., Friedman E., Samowitz W., Robertson M. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell. 1992 Apr 17;69(2):275–281. doi: 10.1016/0092-8674(92)90408-5. [DOI] [PubMed] [Google Scholar]
  18. Li Y., O'Connell P., Breidenbach H. H., Cawthon R., Stevens J., Xu G., Neil S., Robertson M., White R., Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 1995 Jan 1;25(1):9–18. doi: 10.1016/0888-7543(95)80104-t. [DOI] [PubMed] [Google Scholar]
  19. Lowy D. R., Willumsen B. M. Function and regulation of ras. Annu Rev Biochem. 1993;62:851–891. doi: 10.1146/annurev.bi.62.070193.004223. [DOI] [PubMed] [Google Scholar]
  20. Lutchman M., Rouleau G. A. Neurofibromatosis type 2: a new mechanism of tumor suppression. Trends Neurosci. 1996 Sep;19(9):373–377. doi: 10.1016/S0166-2236(96)10044-8. [DOI] [PubMed] [Google Scholar]
  21. Maekawa M., Li S., Iwamatsu A., Morishita T., Yokota K., Imai Y., Kohsaka S., Nakamura S., Hattori S. A novel mammalian Ras GTPase-activating protein which has phospholipid-binding and Btk homology regions. Mol Cell Biol. 1994 Oct;14(10):6879–6885. doi: 10.1128/mcb.14.10.6879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Maltby E. L., Ironside J. W., Battersby R. D. Cytogenetic studies in 50 meningiomas. Cancer Genet Cytogenet. 1988 Apr;31(2):199–210. doi: 10.1016/0165-4608(88)90218-x. [DOI] [PubMed] [Google Scholar]
  23. Marchuk D. A., Saulino A. M., Tavakkol R., Swaroop M., Wallace M. R., Andersen L. B., Mitchell A. L., Gutmann D. H., Boguski M., Collins F. S. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991 Dec;11(4):931–940. doi: 10.1016/0888-7543(91)90017-9. [DOI] [PubMed] [Google Scholar]
  24. Martuza R. L., Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988 Mar 17;318(11):684–688. doi: 10.1056/NEJM198803173181106. [DOI] [PubMed] [Google Scholar]
  25. Moodie S. A., Paris M., Villafranca E., Kirshmeier P., Willumsen B. M., Wolfman A. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets. Oncogene. 1995 Aug 3;11(3):447–454. [PubMed] [Google Scholar]
  26. Mulvihill J. J., Parry D. M., Sherman J. L., Pikus A., Kaiser-Kupfer M. I., Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 1990 Jul 1;113(1):39–52. doi: 10.7326/0003-4819-113-1-39. [DOI] [PubMed] [Google Scholar]
  27. Murphy M., Chen J. N., George D. L. Establishment and characterization of a human leptomeningeal cell line. J Neurosci Res. 1991 Nov;30(3):475–483. doi: 10.1002/jnr.490300304. [DOI] [PubMed] [Google Scholar]
  28. Murphy M., Pykett M. J., Harnish P., Zang K. D., George D. L. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993 Sep;4(9):715–722. [PubMed] [Google Scholar]
  29. O'Rahilly R., Müller F. The meninges in human development. J Neuropathol Exp Neurol. 1986 Sep;45(5):588–608. [PubMed] [Google Scholar]
  30. Peyrard M., Fransson I., Xie Y. G., Han F. Y., Ruttledge M. H., Swahn S., Collins J. E., Dunham I., Collins V. P., Dumanski J. P. Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet. 1994 Aug;3(8):1393–1399. doi: 10.1093/hmg/3.8.1393. [DOI] [PubMed] [Google Scholar]
  31. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  32. Salgaller M., Agius L., Yates A., Pearl D., Roberts W., Stephens R. Application of automated image analysis to demonstrate the correlation between ras p21 expression and severity of gliomas. Biochem Biophys Res Commun. 1990 Jun 15;169(2):482–491. doi: 10.1016/0006-291x(90)90357-s. [DOI] [PubMed] [Google Scholar]
  33. Scheithauer B. W. Tumors of the meninges: proposed modifications of the World Health Organization classification. Acta Neuropathol. 1990;80(4):343–354. doi: 10.1007/BF00307686. [DOI] [PubMed] [Google Scholar]
  34. Stacey D. W., Feig L. A., Gibbs J. B. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol. 1991 Aug;11(8):4053–4064. doi: 10.1128/mcb.11.8.4053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ståhle-Bäckdhal M., Inoue M., Zedenius J., Sandstedt B., DeMarco L., Flam F., Silfverswärd C., Andrade J., Friedman E. Decreased expression of Ras GTPase activating protein in human trophoblastic tumors. Am J Pathol. 1995 May;146(5):1073–1078. [PMC free article] [PubMed] [Google Scholar]
  36. Takahashi K., Suzuki H., Hatori M., Abe Y., Kokubun S., Sakurai M., Shibahara S. Reduced expression of neurofibromin in the soft tissue tumours obtained from patients with neurofibromatosis type I. Clin Sci (Lond) 1995 May;88(5):581–585. doi: 10.1042/cs0880581. [DOI] [PubMed] [Google Scholar]
  37. Tikoo A., Varga M., Ramesh V., Gusella J., Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem. 1994 Sep 23;269(38):23387–23390. [PubMed] [Google Scholar]
  38. Todo T., Adams E. F., Fahlbusch R., Dingermann T., Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996 May;84(5):852–859. doi: 10.3171/jns.1996.84.5.0852. [DOI] [PubMed] [Google Scholar]
  39. Trahey M., McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science. 1987 Oct 23;238(4826):542–545. doi: 10.1126/science.2821624. [DOI] [PubMed] [Google Scholar]
  40. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  41. Vogel K. S., Brannan C. I., Jenkins N. A., Copeland N. G., Parada L. F. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell. 1995 Sep 8;82(5):733–742. doi: 10.1016/0092-8674(95)90470-0. [DOI] [PubMed] [Google Scholar]
  42. Weissbach L., Settleman J., Kalady M. F., Snijders A. J., Murthy A. E., Yan Y. X., Bernards A. Identification of a human rasGAP-related protein containing calmodulin-binding motifs. J Biol Chem. 1994 Aug 12;269(32):20517–20521. [PubMed] [Google Scholar]
  43. Xu G. F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., White R., Weiss R., Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990 Nov 16;63(4):835–841. doi: 10.1016/0092-8674(90)90149-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES